Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Deferred Revenue (2016 - 2025)

Guided Therapeutics' Current Deferred Revenue history spans 16 years, with the latest figure at $689318.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 7.82% year-over-year to $689318.0; the TTM value through Sep 2025 reached $689318.0, down 7.82%, while the annual FY2024 figure was $849000.0, 100.13% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $689318.0 at Guided Therapeutics, up from $679318.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $514.0 million in Q1 2022 and bottomed at $62000.0 in Q1 2021.
  • The 5-year median for Current Deferred Revenue is $509101.0 (2022), against an average of $27.5 million.
  • The largest annual shift saw Current Deferred Revenue skyrocketed 828932.26% in 2022 before it tumbled 99.91% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $337315.0 in 2021, then surged by 50.93% to $509101.0 in 2022, then dropped by 16.67% to $424225.0 in 2023, then soared by 100.13% to $849000.0 in 2024, then fell by 18.81% to $689318.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Current Deferred Revenue are $689318.0 (Q3 2025), $679318.0 (Q2 2025), and $670000.0 (Q1 2025).